September 5, 2022 - Omnix Medical

STUDY: In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

The rapid worldwide spread of antimicrobial resistance (AMR) underscores the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. Our Scientists at Omnix Medical have published a study demonstrating the potent antimicrobial activity of the novel peptide OMN6 against a wide array of drug-resistant Acinetobacter baumannii. Results point to OMN6 as a novel antimicrobial […]

Contact Us

Reach US

A-2-Z - Digital Accessibility and Marketing

Omnix Medical Ltd. is committed to making its website and all its electronic information easier to use and more accessible for people with disabilities. The company’s website was created and/or updated according to the provisions of the Equal Rights for People with Disabilities Law, 5748-1998, and the delegated legislation stemming from it, and it fully complies with the W3C Web Content Accessibility Guidelines 2.0, AA level.

Omnix Medical Ltd. will continue its efforts to constantly improve the accessibility of its website and information in the belief that it is our collective moral obligation to allow seamless, accessible, and unhindered use also for those of us with disabilities.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).